Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors

Fernandez, A., Karavitaki, N. & Wass, J. A. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. 72, 377–382 (2010).

Melmed, S. et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273–288 (2011).

Molitch, M. E. Diagnosis and treatment of pituitary adenomas: a review. JAMA 317, 516–524 (2017).

Villa, C. et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Arch. 475, 687–692 (2019).

Lopes, M. B. S. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 134, 521–535 (2017).

Raverot, G. et al. European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol. 178, G1–g24 (2018).

Matsuno, A., Sasaki, T. & Kirino, T. Plurihormonal pituitary tumor. J. Neurosurg. 90, 608–609 (1999).

Scheithauer, B. W. et al. Plurihormonal pituitary adenomas. Semin. Diagn. Pathol. 3, 69–82 (1986).

Trouillas, J. et al. How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020. Cancers 12, 514 (2020).

Katznelson, L. et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3933–3951 (2014).

Fukuoka, H. et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J. Clin. Invest. 121, 4712–4721 (2011).

Tatsi, C. & Stratakis, C. A. The genetics of pituitary adenomas. J. Clin. Med. 9, 30 (2019).

Song, Z. J. et al. The genome-wide mutational landscape of pituitary adenomas. Cell Res. 26, 1255–1259 (2016).

Zhang, Q. et al. Germline mutations in CDH23, encoding cadherin-related 23, are associated with both familial and sporadic pituitary adenomas. Am. J. Hum. Genet. 100, 817–823 (2017).

Ma, Z. Y. et al. Recurrent gain-of-function USP8 mutations in Cushing’s disease. Cell Res. 25, 306–317 (2015).

Reincke, M. et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat. Genet. 47, 31–38 (2015).

Albani A. et al. The USP8 mutational status may predict long-term remission in patients with Cushing’s disease. Clin. Endocrinol. https://doi.org/10.1111/cen.13802 (2018).

Cui, Y. et al. Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors. Neuro. Oncol. 23, 1859–1871 (2021).

Neou, M. et al. Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 37, 123–134.e5 (2020).

Zhang, B. et al. Proteogenomic characterization of human colon and rectal cancer. Nature 513, 382–387 (2014).

Clark, D. J. et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell 179, 964–983.e31 (2019).

Cao, L. et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell 184, 5031–5052.e26 (2021).

Weinstein, J. N. et al. The cancer genome atlas pan-cancer analysis project. Nat. Genet. 45, 1113–1120 (2013).

Petralia, F. et al. Integrated proteogenomic characterization across major histological types of pediatric brain cancer. Cell 183, 1962–1985.e31 (2020).

Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173, 371–385.e18 (2018).

Ronchi, C. L. et al. Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. Eur. J. Endocrinol. 174, 363–372 (2016).

Bi, W. L. et al. Landscape of genomic alterations in pituitary adenomas. Clin. Cancer Res. 23, 1841–1851 (2017).

Hage, M. et al. Genomic alterations and complex subclonal architecture in sporadic GH-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 103, 1929–1939 (2018).

Lu, C. et al. Loss of Gsα impairs liver regeneration through a defect in the crosstalk between cAMP and growth factor signaling. J. Hepatol. 64, 342–351 (2016).

Xie, T., Chen, M., Zhang, Q. H., Ma, Z. & Weinstein, L. S. Beta cell-specific deficiency of the stimulatory G protein alpha-subunit Gsalpha leads to reduced beta cell mass and insulin-deficient diabetes. Proc. Natl. Acad. Sci. USA 104, 19601–19606 (2007).

Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572–1573 (2010).

Simurda, T. et al. Genetic variants in the FGB and FGG genes mapping in the beta and gamma nodules of the fibrinogen molecule in congenital quantitative fibrinogen disorders associated with a thrombotic phenotype. Int. J. Mol. Sci. 21, 4616 (2020).

Sivapalaratnam, S. et al. Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia. Blood 129, 520–524 (2017).

Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178–196 (2014).

Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. Emt: 2016. Cell 166, 21–45 (2016).

Lambert, A. W., Pattabiraman, D. R. & Weinberg, R. A. Emerging biological principles of metastasis. Cell 168, 670–691 (2017).

Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).

Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 20, 69–84 (2019).

Chen, C., Zhao, S., Karnad, A. & Freeman, J. W. The biology and role of CD44 in cancer progression: therapeutic implications. J. Hematol. Oncol. 11, 64 (2018).

Gillette, M. A. et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell 182, 200–225.e35 (2020).

Huang, C. et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell 39, 361–379.e16 (2021).

Xu, J. Y. et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell 182, 245–261.e17 (2020).

Feelders, R. A. et al. Advances in the medical treatment of Cushing’s syndrome. Lancet Diabetes Endocrinol. 7, 300–312 (2019).

Chen, Z. et al. Transcription factor ASCL1 acts as a novel potential therapeutic target for the treatment of the Cushing’s disease. J. Clin. Endocrinol. Metab. 107, 2296–2306 (2022).

Holland, C. H., Szalai, B. & Saez-Rodriguez, J. Transfer of regulatory knowledge from human to mouse for functional genomics analysis. Biochim. Biophys. Acta Gene Regul. Mech. 1863, 194431 (2020).

Schubert, M. et al. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat. Commun. 9, 20 (2018).

Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).

Cerezo, M. et al. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Nat. Med. 24, 1877–1886 (2018).

Abril-Rodriguez, G. & Ribas, A. SnapShot: immune checkpoint inhibitors. Cancer Cell 31, 848–848.e1 (2017).

Ferreira, R., Lively, S. & Schlichter, L. C. IL-4 type 1 receptor signaling up-regulates KCNN4 expression, and increases the KCa3.1 current and its contribution to migration of alternative-activated microglia. Front. Cell Neurosci. 8, 183 (2014).

Garces de Los Fayos Alonso, I. et al. The role of activator protein-1 (AP-1) family members in CD30-positive lymphomas. Cancers (Basel) 10, 93 (2018).

Goenka, S. & Kaplan, M. H. Transcriptional regulation by STAT6. Immunol. Res. 50, 87–96 (2011).

de Heer, E. & Peters, D. J. Innate immunity as a driving force in renal disease. Kidney Int. 73, 7–8 (2008).

Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).

Ben-Shlomo, A., Liu, N. A. & Melmed, S. Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas. Pituitary 20, 93–99 (2017).

Ho, K. K. Y., Gadelha, M., Kaiser, U. B., Reincke, M. & Melmed, S. The NETting of pituitary adenoma: a gland illusion. Pituitary 25, 349–351 (2022).

Suteau, V. et al. Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor. Cancer Immunol. Immunother. 69, 2053–2061 (2020).

Ilie, M. D., Vasiljevic, A., Jouanneau, E. & Raverot, G. Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review. Endocr. Relat. Cancer 29, 415–426 (2022).

Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563–580 (2019).

Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554.e12 (2016).

Satpathy, S. et al. A proteogenomic portrait of lung squamous cell carcinoma. Cell 184, 4348–4371.e40 (2021).

Spada, A. et al. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J. Clin. Endocrinol. Metab. 71, 1421–1426 (1990).

Wang, J. et al. ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway. Biomed. Pharmacother. 97, 1066–1077 (2018).

Rai, A. et al. Phosphorylated EGFR (pEGFR T693) as a novel predictor of recurrence in non-functioning pituitary adenomas. Front. Endocrino. 12, 708111 (2021).

Almeida, J. P. et al. Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers. Pituitary 22, 514–519 (2019).

Balogun, J. A. et al. Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics. Endocr. Pathol. 26, 63–70 (2015).

Tebani, A. et al. Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis. Acta Neuropathol. Commun. 9, 181 (2021).

Vergeer, R. A. et al. Detection by fluorescence of pituitary neuroendocrine tumour (PitNET) tissue during endoscopic transsphenoidal surgery using bevacizumab-800CW (DEPARTURE trial): study protocol for a non-randomised, non-blinded, single centre, feasibility and dose-finding trial. BMJ Open 11, e049109 (2021).

Wang Y. et al. Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma: case report and literature review. World Neurosurg 19, S1878–8750 (2019)

Giustina, A. et al. Multidisciplinary management of acromegaly: A consensus. Rev. Endocr. Metab. Disord. 21, 667–678 (2020).

Luo, P., Zhang, L., Yang, L., An, Z. & Tan, H. Progress in the pathogenesis, diagnosis, and treatment of tsh-secreting pituitary neuroendocrine tumor. Front. Endocrinol. 11, 580264 (2020).

Melmed, S. Pituitary-tumor endocrinopathies. N. Engl. J. Med. 382, 937–950 (2020).

Nieman, L. K. et al. Treatment of cushing’s syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 100, 2807–2831 (2015).

Ntali, G., Capatina, C., Grossman, A. & Karavitaki, N. Clinical review: Functioning gonadotroph adenomas. J. Clin. Endocrinol. Metab. 99, 4423–4433 (2014).

Hardy, J. Atlas of transsphenoidal microsurgery in pituitary tumors. (Igaku-Shoin Medical Publishers, New York, 1991).

Knosp, E., Steiner, E., Kitz, K. & Matula, C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33, 610–617 (1993).

Sims, D., Sudbery, I., Ilott, N. E., Heger, A. & Ponting, C. P. Sequencing depth and coverage: key considerations in genomic analyses. Nat. Rev. Genet. 15, 121–132 (2014).

Gao, Q. et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell 179, 561–577.e22 (2019).

Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).

Auton, A. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).

Wiśniewski, J. R., Zougman, A., Nagaraj, N. & Mann, M. Universal sample preparation method for proteome analysis. Nat. Methods 6, 359–362 (2009).

Feng, J. et al. Firmiana: towards a one-stop proteomic cloud platform for data processing and analysis. Nat. Biotechnol. 35, 409–412 (2017).

Perkins, D. N., Pappin, D. J., Creasy, D. M. & Cottrell, J. S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551–3567 (1999).

Käll, L., Canterbury, J. D., Weston, J., Noble, W. S. & MacCoss, M. J. Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat. Methods 4, 923–925 (2007).

Taus, T. et al. Universal and confident phosphorylation site localization using phosphoRS. J. Proteome Res. 10, 5354–5362 (2011).

Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).

Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).

Croft, D. et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 42, D472–D477 (2014).

Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).

Diaz-Gay, M. et al. Mutational signatures in cancer (MuSiCa): a web application to implement mutational signatures analysis in cancer samples. BMC Bioinformatics 19, 224 (2018).

Mertins, P. et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55–62 (2016).

Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).

Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).

Kassambara, A. & Mundt, F. Factoextra: Extract and Visualize the Results of Multivariate Data Analyses. https://CRAN.R-project.org/package=factoextra (2020).

Xu, T. et al. CancerSubtypes: an R/Bioconductor package for molecular cancer subtype identification, validation and visualization. Bioinformatics 33, 3131–3133 (2017).

Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108–112 (2009).

Hänzelmann, S., Castelo, R. & Guinney, J. J. B. B. GSVA: Gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics 14, 7 (2013).

Horn, H. et al. KinomeXplorer: an integrated platform for kinome biology studies. Nat. Methods 11, 603–604 (2014).

Hornbeck, P. V. et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512–D520 (2015).

Garcia-Alonso, L., Holland, C. H., Ibrahim, M. M., Turei, D. & Saez-Rodriguez, J. Benchmark and integration of resources for the estimation of human transcription factor activities. Genome Res. 29, 1363–1375 (2019).

Ellis, M. J. et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J. Clin. Oncol. 35, 1061–1069 (2017).

Krug, K. et al. Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy. Cell 183, 1436–1456.e31 (2020).

Seckinger, A. et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood 120, 1087–1094 (2012).

Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).

Humphries, M. P., Maxwell, P. & Salto-Tellez, M. QuPath: The global impact of an open source digital pathology system. Comput. Struct. Biotechnol. J. 19, 852–859 (2021).

Wilcox, R. R. Comparing dependent robust correlations. Br. J. Math. Stat. Psychol. 69, 215–224 (2016).

Ma, J. et al. iProX: an integrated proteome resource. Nucleic Acids Res. 47, D1211–D1217 (2019).